STOP— a training intervention to optimise treatment for smoking cessation in community pharmacies: cluster randomised controlled trial
Jumbe S. et al, (2022), BMC Medicine, 20
Prediction models for individual-level healthcare costs associated with cardiovascular events in the UK
Zhou J. et al, (2022), PharmacoEconomics
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
Blazing M. et al, (2022), The Lancet, 400, 832 - 845
Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017
PREISS D. et al, (2022), Heart
Statistical models for the deterioration of kidney function in a primary care population: A retrospective database analysis
Oke JL. et al, (2022), F1000Research, 8, 1618 - 1618
Hospital costs associated with adverse events in people with diabetes in the UK
Keng MJ. et al, (2022), Diabetes, Obesity and Metabolism
BEHRTDAY: Dynamic Mortality Risk Prediction using Time-Variant COVID-19 Patient Specific Trajectories
Azhir A. et al, (2022), https://knowledge.amia.org/75287-amia-1.4633888?qr=1
Using Shapes of COVID-19 Positive Patient-Specific Trajectories for Mortality Prediction
Azhir A. et al, (2022), https://knowledge.amia.org/75287-amia-1.4633888?qr=1
CALIBRATING CARDIOVASCULAR DISEASE POLICY MODEL USING LARGE COHORT DATA
Wu R. et al, (2022), VALUE IN HEALTH, 25, S16 - S16
EXCESS ANNUAL HOSPITAL COSTS DUE TO CARDIOVASCULAR EVENTS IN A CONTEMPORARY UK POPULATION TO INFORM HEALTH TECHNOLOGY ASSESSMENTS
Zhou J. et al, (2022), VALUE IN HEALTH, 25, S12 - S12
Impact of adverse events on hospital costs and health-related quality of life in people with diabetes
Keng MJ. et al, (2022), DIABETES RESEARCH AND CLINICAL PRACTICE, 186
P55 Excess Annual Hospital Costs Due to Cardiovascular Events in a Contemporary UK Population to Inform Health Technology Assessments
Zhou J. et al, (2022), Value in Health, 25, S12 - S12
P70 Calibrating Cardiovascular Disease Policy Model Using Large Cohort Data
Wu R. et al, (2022), Value in Health, 25, S16 - S16
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
HPS3/TIMI55-REVEAL Collaborative Group Writing Committee: None. et al, (2021), Eur Heart J
Decrements in health‐related quality of life associated with adverse events in people with diabetes
Keng MJ. et al, (2021), Diabetes, Obesity and Metabolism
Gaps in antihypertensive and statin treatments and benefits of optimisation: a modelling study in a 1 million ethnically diverse urban population in UK.
Wu R. et al, (2021), BMJ open, 11, e052884 - e052884
A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts
Wu R. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3149 - 3149
Benefits from optimised antihypertensive and statin treatment in high risk people
Wu R. et al, (2021), EUROPEAN HEART JOURNAL, 42, 2728 - 2728
Impact of adverse events on quality of life and hospital costs in secondary cardiovascular disease prevention
Lui NMJ. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3159 - 3159